Review Article

Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis

Elham Emami¹, Saeid Heidari-Sournalsjian²⁺, Catherine MT Sherwin³

¹Department of Pediatric Nephrology, Emam Hossein Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
³Department of Pediatric Clinical Pharmacology, Department of Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton Children’s Hospital, One Children’s Plaza, Dayton, Ohio, USA

Article history:
Received: Dec 22, 2021
Received in revised form: Feb 16, 2022
Accepted: Feb 17, 2022
AJP, Vol. 12, No. 6, Nov-Dec 2022, 576-588.
https://dx.doi.org/10.22038/AJP.2022.20049

* Corresponding Author:
Tel: +98-9131833509
Fax: +98-383351031
heidari_62@yahoo.com

Keywords:
Chronic kidney disease
Hemodialysis
Curcumin
Inflammation

Abstract

Objective: This study was designed to determine the association curcumin has on pro-inflammatory biomarkers in patients with chronic kidney disease (CKD) and in those receiving hemodialysis (HD).

Materials and Methods: This meta-analysis was undertaken following PRISMA guidelines. An extensive systematic review was undertaken until 10/11/2021 using PubMed, Web of Science (ISI), and Scopus databases. The standardized mean difference (SMD) and 95% confidence intervals (CI) were used to estimate the overall effect size of curcumin on serum high-sensitivity C-reactive protein (hs-CRP), and pro-inflammatory cytokines including interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) in patients with CKD and those receiving HD.

Results: Overall, ten randomized controlled trials (RCTs) comprising 523 patients were incorporated into the systematic review and meta-analysis. The results showed that when compared with control groups, there was no significant effect observed linking curcumin and IL-6 (SMD = 0.24%, 95% CI = -0.14 to 0.62, p = 0.221), TNF-α (SMD = 0.11%, 95% CI = -0.19 to 0.40, p = 0.480) or hs-CRP (SMD = -0.17%, 95% CI = -0.36 to 0.03, p = 0.093). The analysis determined no publication bias related to the influence of curcumin on IL-6, TNF-α or acute phase reactant, hs-CRP. The Egger’s and Begg’s test results were not statistically significant (p>0.20).

Conclusion: In patients with CKD and those receiving HD, the use of curcumin supplementation has no statistically significant effect on the anti-inflammatory biomarkers reviewed in this study.

Please cite this paper as:
Emami E, Heidari-Soureshjani S, Sherwin C. Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis. Avicenna J Phytomed, 2022; 12(6): 576-588.
Anti-inflammatory response to curcumin hemodialysis

Introduction

Chronic kidney disease (CKD) is unrivaled as one of the most significant health challenges worldwide that contribute to overall morbidity and mortality. CKD is an irreversible and progressive disease considered a significant risk factor for many life-threatening diseases. This includes cardiovascular disease (disorders of the heart and blood vessels) and mineral and bone disorders (Ammirati, 2020; Collaboration, 2020; Hasan et al., 2018; Miller, 2014). Patients are generally offered different treatment options following CKD development, such as hemodialysis (HD). CKD leads to social impairment depressive symptoms and can be a substantial financial burden. Patients’ other complications and issues include pain, weakness after dialysis, anemia, and recurring infections. Low medication adherence can worsen a patient’s condition and considerably reduce his/her quality of life (Bartaula et al., 2019; Moreno Velásquez et al., 2019; Pretto et al., 2020).

Given the overall morbidity and mortality associated with CKD and the significant impact on affected patients, this disease deserves far more awareness within health policy making-decision. This is because it is largely preventable, and effective treatments are available that improve patients' quality of life (Corsonello et al., 2020). The choice of safe and effective medications for this disease involves determining various aspects such as kidney function and monitoring for declines, as this induces changes in drug pharmacokinetics and subsequent drug effectiveness. Appropriate administration of drugs when managing other comorbid conditions and uremic complications is essential (Whittaker et al., 2018). This is because some medications induce drug-drug interactions, and some procedures result in undesirable or harmful effects that increase the consequences of the potential deterioration of the disease resulting in hospital admission and extended lengths of hospital stays (Subeesh et al., 2020). It is recommended to use disease-appropriate, safe, effective treatments and complementary therapies.

Complementary and alternative medicines are becoming increasingly popular worldwide, primarily herbal medicines also called phytotherapy (Welz et al., 2018; Yuan et al., 2016). Among these is curcumin, a yellow phytochemical produced by Curcuma longa, a member of the ginger family (Zingiberaceae). It has been reported to have a beneficial effect on renal diseases and to have anti-inflammatory and antioxidant properties (L. Alvarenga et al., 2020; Bagherniya et al., 2021; Mohammad pour et al., 2019; Najafi et al., 2015). However, there is a knowledge gap, and there are still ambiguous aspects to reports related to the use of this herb. Some studies have shown that it can downregulate the pro-inflammatory cytokines tumor necrosis factor α (TNF-α) and interleukin-1 (IL-1) but that it does not affect interleukin 6 (IL-6) and interleukin-8 (IL-8) (Gorabi et al., 2021). Other studies have reported that curcumin does not reduce inflammation or oxidative stress markers (Rodrigues et al., 2021).

In patients with CKD and those receiving HD, their immune system response activity is disrupted and this leads to pro-inflammatory cytokine dysregulation and a state of persistent inflammation. This is associated with complications, including atherosclerotic vascular disease, protein-energy wasting, depression, and osteoporosis (Carrero et al., 2008; Tinti et al., 2021). Based on the global prevalence of CKD and the persistent need to improve treatment, this meta-analysis systematically investigates the consequence of curcumin supplementation on pro-inflammatory constituents to improve the patients’ conditions with CKD.

Materials and Methods

Data sources and search strategy
The present systematic review and meta-analysis were executed using PRISMA guidelines (http://prisma-statement.org/prisastatement/Checklist.aspx). An extensive systematic review was undertaken until 10/11/2021 using Web of Science (ISI), PubMed, and Scopus databases. These central and MeSH keywords were used in the search: (“chronic kidney diseases” OR “chronic kidney insufficiency” OR “chronic renal diseases” OR “chronic renal insufficiency” OR *dialysis* OR “hemodialysis” OR “renal dialysis” OR “extracorporeal dialysis”) AND (“curcumin” OR “curcuma” OR Curcuma longa” OR “turmeric AND ( “anti-inflammatory” OR “inflammation” OR *inflammatory cytokine* OR CRP OR “c-reactive protein” OR “hs-CRP” OR “interleukin-1” OR “interleukin-6” OR “IL-1” OR tumor necrosis factor OR TNF)).

Study selection

Available peer-reviewed publications were imported into EndNote X8 (8 November 2016, Thomson Reuters) to detect and remove identical publications. Two investigators objectively screened the titles and abstracts of the reported research established by the inclusion and exclusion criteria. Based on inclusion criteria, clinical trials that addressed the anti-inflammatory response associated with curcumin supplementation in patients with CKD receiving HD were included in the systematic review and meta-analysis. Articles not published in English were among the study's exclusion criteria. Publications in the format of letters to the editor, case reports, narrative reviews, and studies involving animals were excluded from the study. The full texts of all eligible publications were independently reviewed. A consensus was achieved for any potential disagreement during the review through discussion with a third team member. The flowchart used for the examination strategy is illustrated in Figure 1.

Figure 1. Flowchart for including studies in the meta-analysis
Anti-inflammatory response to curcumin hemodialysis

Data extraction and quality assessment
Two researchers extracted the data objectively, and any inconsistencies were resolved by discussion. For each publication and study included, the following data were extracted: the first author's details, year of publication, country of study origin, mean age of study population, sample size, length/time of follow-up, curcumin dosage (mg/day), duration of intervention, and the mean and standard deviation (±SD) level of the pro-inflammatory biomarkers before and following the intervention.

Statistical analysis
The standardized mean difference (SMD) and 95% confidence intervals (CI) were used to estimate the overall effect size of curcumin on serum high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), TNF-α in patients with CKD receiving HD. When studies did not report the ±SD of the mean difference, this was calculated by SD² = [(SD baseline² + SD final²) - (2 × 0.8 × SD baseline × SD final)]. The heterogeneity of studies was tested using Cochran’s Q test (reported by chi-square, with p<0.1 considered significant) and by estimating the statistic I². Begg’s and Egger’s tests were used to estimate potential publication and accumulation bias. All statistical analyses were accomplished using Stata 14.0 (Stata LLC, College Station, TX, USA), with p<0.05 judged statistically significant.

Results
Search results and characteristics of selected studies
The PRISMA flowchart is illustrated in Figure 1. The initial electronic search retrieved 557 titles/abstracts. From the total articles retrieved, 264 articles were removed due to duplicate titles. Some other titles/abstracts were also excluded (n= 6) as they did not match our study aims: (Jiménez-Osorio et al., 2016; Pakfetrat et al., 2015; Salarolli et al., 2021; Shelmadine et al., 2017; Vanaie et al., 2019; Yang et al., 2015). In total, ten clinical trials (which involved 523 patients) were incorporated into the meta-analysis (L. Alvarenga et al., 2020; Kabodan et al., 2018; Khajehdehi et al., 2011; Moreillon et al., 2013; Pakfetrat et al., 2014; Rodrigues et al., 2021; Samadian et al., 2017; Shafabakhsh et al., 2020; Vafadar-Afshar et al., 2021; Vafadar Afshar et al., 2020). From the selected trials, three studies investigated IL-6 (Kabodan et al., 2018; Moreillon et al., 2013; Vafadar-Afshar et al., 2021), eight studies involved hs-CRP (L. Alvarenga et al., 2020; Kabodan et al., 2018; Moreillon et al., 2013; Pakfetrat et al., 2014; Rodrigues et al., 2021; Samadian et al., 2017; Shafabakhsh et al., 2020; Vafadar Afshar et al., 2020) and four studies analyzed TNF-α (Khajehdehi et al., 2011; Moreillon et al., 2013; Pakfetrat et al., 2014; Vafadar-Afshar et al., 2021) (Figure 1).

All studies incorporated into this study were published between 2013 and 2021. Detailed data from the studies, including sample size, length/time of follow-up, number of participants in the intervention and control groups, study design, curcumin dose and duration of administration, year of study, and location of the study are summarized in Table 1.

The outcome of the meta-analyses of the effect of curcumin on serum level of IL-6
Three studies examined the influence of curcumin and IL-6, with 71 participants in the intervention group and 70 participants in the control group. The results revealed there was no significant increase in the serum level of IL-6 when matched against the control group (SMD = 0.24%, 95% CI = -0.14 to 0.62, p=0.221) (Figure 2). Analysis of the study, investigating the impact of curcumin on IL-6, determined there was publication bias. The conclusion of Egger’s test was equal to (p =0.508), and Begg’s test (p =0.602) produced no statistically significant results (Figure 3).
| Study author | Year | Country   | Gender                        | Age mean | N   | Renal disorder | Total dose (per day) | Follow up | Intervention group mean±SD | Control group mean±SD |
|--------------|------|-----------|-------------------------------|----------|-----|----------------|---------------------|-----------|----------------------------|----------------------|
| **Interleukin 6 (IL-6)** |      |           |                               |          |     |                |                     |           |                            |                      |
| Moreillon (Moreillon et al., 2013) | 2013 | USA       | NA*                           | 56       | 16  | CKD**          | 824 mg              | 8 weeks   | 35.5±46.7                  | 30.7±46.7            |
| Samadian (Samadian et al., 2017)  | 2017 | Iran      | NA                            | 49       | 71  | HD***          | 1500 mg             | 12 weeks  | 5.73±5.16                  | 35.37±53.59         |
| Vafadar-Afshar (Vafadar-Afshar et al., 2021) | 2021 | Iran     | 62.97% male 37.03% female   | 57       | 54  | HD             | 120 mg              | 12 weeks  | 34.4±4.8                   | 21.6±2.51            |
| **Tumor necrosis factor α (TNF-α)** |      |           |                               |          |     |                |                     |           |                            |                      |
| Khajehdehi (Khajehdehi et al., 2011) | 2011 | Iran      | 55% male and 45% female     | 52       | 40  | CKD           | 1500 mg             | 2 months  | 12.8±2.9                   | 18±24.1              |
| Moreillon (Moreillon et al., 2013) | 2013 | USA       | NA                           | 56       | 16  | CKD           | 824 mg              | 8 weeks   | 31.4±43.5                  | 34.4±40.5            |
| Pakfetrat (Pakfetrat et al., 2014) | 2014 | Iran      | 60% male and 40% female     | 53       | 100 | HD             | 1500 mg             | 8 weeks   | 36.36±42.38                | 84.11±65.14         |
| Vafadar-Afshar (Vafadar-Afshar et al., 2021) | 2021 | Iran     | 62.97% male 37.03% female   | 57       | 54  | HD             | 120 mg              | 12 weeks  | 43.4±6.79                  | 27.8±3.05            |
| **High-sensitivity C-reactive protein (hs-CRP)** |      |           |                               |          |     |                |                     |           |                            |                      |
| Moreillon (Moreillon et al., 2013) | 2013 | USA       | NA                           | 56       | 16  | CKD           | 824 mg              | 8 weeks   | 2±1                        | 3±2                  |
| Pakfetrat (Pakfetrat et al., 2014) | 2014 | Iran      | 60% male and 40% female     | 53       | 100 | HD             | 1500 mg             | 8 weeks   | 10.8±9.7                   | 7±8.9               |
| Samadian (Samadian et al., 2017)   | 2017 | Iran      | NA                           | 49       | 71  | HD             | 1500 mg             | 12 weeks  | 1.23±82.3                  | 53±4.2              |
| Kabodan (Kabodan et al., 2018)     | 2018 | Iran      | NA                           | NA       | 64  | HD             | 800 mg              | 8 weeks   | 22.1±37                    | 19±26.76            |
| Alvarenga (L. Alvarenga et al., 2020) | 2020 | Brazil    | NA                           | NA       | 28  | HD             | 2500 mg             | 12 weeks  | 3.8±2.15                   | 2±1.35              |
| Shafabakhsh (Shafabakhsh et al., 2020) | 2020 | Iran      | 60.4% male 39.6% female     | 57       | 53  | HD             | 80 mg               | 12 weeks  | 5.4±2.5                    | 4.5±2               |
| Vafadar-Afshar (Vafadar Afshar et al., 2020) | 2020 | Iran     | 62.97% male 37.03% female   | 57       | 54  | HD             | 120 mg              | 12 weeks  | 13±8.5                     | 6.9±3.58            |
| Rodrigues (Rodrigues et al., 2021) | 2021 | Brazil    | 67.45% male 32.55% female   | 53       | 43  | HD             | 1000 mg             | 12 weeks  | 5.2±8.5                    | 5.6±8.5             |

* NA; Not applicable, **CKD; Chronic kidney disease, ***HD; Hemodialysis
Results from the meta-analyses of curcumin’s effect on serum TNF-α

In this meta-analysis, four studies investigated the influence of curcumin supplementation on TNF-α. There were 106 participants within the intervention group and 104 participants in the control group. The findings exhibited no significant change in the serum level of TNF-α matched to the control group (SMD = 0.11%, 95% CI = -0.19 to 0.40, P = 0.480) (Figure 4). There was no publication bias. The result of Egger’s test was equal to (p = 0.342), and Begg’s test (p=0.308) produced no statistically significant results (Figure 5).

Outcome from meta-analyses of the effect of curcumin on serum levels of hs-CRP

Within this review, eight studies assessed the relationship between curcumin supplementation and the acute phase reactant, hs-CRP. There were 214 participants within the intervention group and 215 participants within the control
The results found no significant reduction in the serum level of hs-CRP when equated to the control group (SMD = -0.17%, 95% CI = -0.36 to 0.03, p=0.093) (Figure 6). Evaluation of the trials reporting the effect of curcumin on the acute phase reactant, hs-CRP, showed no publication bias. The p-value of Egger’s test was equal to p=0.982, and Begg’s test (p=0.902) yielded no statistically significant results (Figure 7).

Figure 4. Forest plot representing the SMD and 95% CI for the impact of curcumin on TNF-α

Figure 5. Evaluation of publication bias in the included studies for the consequence of curcumin on TNF-α
Anti-inflammatory response to curcumin hemodialysis

![Forest plot](image1)

Figure 6. Forest plot presenting SMD and 95% CI for the outcome of curcumin on hs-CRP

![Funnel plot](image2)

Figure 7. Evaluation of publication bias in the included studies for the outcome of curcumin on hs-CRP

Discussion

This systematic review and meta-analysis investigated the consequence of curcumin supplementation on pro-inflammatory cytokines in patients with CKD receiving HD. Curcumin is a bright yellow chemical derived from plants in the *Curcuma longa* species that was suggested to be used as a complementary therapy in multiple diseases. It has been reported to be used safely and efficiently as an adjuvant in multiple autoimmune and inflammatory diseases such as inflammatory bowel disease, sclerosis, psoriasis, osteoarthritis, and systemic lupus erythematosus. It is outlined that the wide range of bioactive substances present in the plant has anti-inflammatory, anti-tumor, and antioxidant effects (Haroyan et al., 2018; Kotha, Luthria, 2019; Kunnumakkara et al., 2017; Marton et al., 2020; J. Sharifi-Rad et al., 2020). However, there remains debate and a lack of consensus regarding curcumin's overall safety and toxicity. There are concerns regarding dosing and
administration and both should be carefully considered to achieve effective therapy and to avoid adverse effects.

Studies have suggested that by targeting specific signalling pathways, curcumin induces anti-inflammatory and antioxidant effects through NF-κB and Nrf-2 modulation in patients with CKD (Rahban et al., 2020; Xu et al., 2021). Various metabolic and biochemical alterations are associated with CKD due to the systemic oxidative stress and inflammation the disease promotes. This progresses the patient’s disease deterioration by directly or indirectly affecting the up-regulation of NF-κB and downregulation of Nrf2. It is proposed that curcumin could be used to reduce the impact of this physiological response (Livía Alvarenga et al., 2018). Even though other studies have reviewed inflammatory factors and various acute phase reactants and cytokines in a range of diseases, this study only investigated factors in patients with CKD and HD receiving curcumin. In this study, there was no significant effect associated with curcumin on IL-6 (SMD = 0.24%, 95% CI = -0.14 to 0.62, p=0.221), TNF-α (SMD = 0.11%, 95% CI = -0.19 to 0.40, P = 0.480) and hs-CRP (SMD = -0.17%, 95% CI = -0.36 to 0.03, p=0.093). Consistent with the results of this study, White et al. reported that turmeric (from the ground up roots of the Curcuma longa plant) and curcumin were not linked with a decrease in several inflammatory markers including hs-CRP (MD -1.44 mg/L, 95%CI -2.94 to 0.06, p=0.06, six studies), CRP (MD -2.71 mg/L, 95%CI -5.73 to 0.31, p=0.08, five studies), IL-1 (MD -4.25 pg/ml, 95%CI -13.32 to 4.82, p=0.36, two studies), TNF α (MD -1.23 pg/ml, 95%CI -3.01 to 0.55, p=0.18, seven studies) and IL-6 (MD -0.71 pg/ml, 95%CI -1.68 to 0.25, p=0.15). These studies were undertaken in patients with chronic inflammatory diseases. In addition, no variations were reported among the interventions using turmeric or curcumin supplementation (White et al., 2019).

A different meta-analysis examining the influence of curcumin on proinflammatory cytokines, reported results that did show a significant reduction in the serum levels of TNF-α (WMD = −1.61 pg/ml, 95% CI = −2.72, −0.51, p<0.001 and IL-1 (WMD = −2.33 pg/ml, 95% CI = −3.33 to −1.34, p<0.001), when matched to the placebo group. However, no significant association was reported concerning the use of curcumin supplementation as well as the reduced and increased levels of IL-6 (WMD = −0.33 pg/ml, 95% CI = −0.99–0.34, P = 0.33) and IL-8 (WMD = 0.52 pg/ml, 95% CI = −1.13–2.17, p=0.53), respectively (Gorabi et al., 2021).

Memarzia et al. suggested that Curcuma longa (turmeric) and curcumin improve the pro-inflammatory activities of IL-4, immunoglobulin E, transforming growth factor-beta, IL-17, and interferon-gamma levels. They outlined that these supplements also reverse impairments in disorders causing disturbances associated with the immune system through antioxidant and anti-inflammatory effects (Memarzia et al., 2021). A different meta-analysis proclaimed the beneficial anti-inflammatory effects of curcumin. Ferguson et al. showed an increase in IL-10 (0.49 pg/ml; 0.10 to 0.88) and a reduction in hs-CRP (−1.55 mg/L; −1.81 to −1.30), IL-8 (−0.54 pg/ml; −0.82 to −0.28), IL-6 (−1.69 pg/ml, −2.56 to −0.82), TNF α (−3.13 pg/ml; −4.62 to −1.64), and monocyte chemoattractant protein-1 (MCP-1/CCL2) (−2.48 pg/ml; −3.96 to −1.00) (Ferguson et al., 2021).

However, according to the results of our extensive analysis, curcumin, in general, has no direct effect on the reduction or regulation of inflammatory factors in the kidney and subsequently in CKD. We acknowledge that there are still contradictions within the published studies. The main issue is that different types of inflammatory factors have been investigated and that they do not all have the same effect on inflammatory processes associated with the disease. The variations

Emami et al.

AJP, Vol. 12, No. 6, Nov-Dec 2022 584
in types of administration and the diversity within the compounds may cause conflicting results between the studies due to the use of different preparations of curcumin in the trials. For example, curcumin as a constituent within formulations has poor solubility and is poorly absorbed when in the free form in the digestive tract. Due to its rapid biotransformation to an inactive metabolite, the administration and formulation used within a study are critical. Recent advances in curcumin nano-formulations have been reported to enhance curcumin's bioavailability and result in encouraging blood levels (Stohs et al., 2020). There remains a lack of data associated with toxicity and potential adverse effects.

Nevertheless, there have been some promising effects associated with curcumin. These appear to be dosage-dependent and require robust dosage studies to be undertaken to determine effectiveness. As outlined, curcumin appears to have dose-dependent limitations due to its bioavailability. This is a crucial factor when considering potential therapeutic outcomes and how this may affect endpoints and results (Gupta et al., 2013; Javad Sharifi-Rad et al., 2020). Furthermore, curcumin dosage is a determinant that induces reactive oxygen species (ROS) generation, inflammatory cytokines, and cell apoptosis (Chan et al., 2006). The most substantial contradictory factor in the results from studies may be due to the severity of CKD and varying stages of kidney disease. Circulating concentrations of inflammatory mediators such as IL-1, IL-6, TNF-α, and hs-CRP are known to be correlated with the severity of the kidney disease (Crewe et al., 2017; Mihai et al., 2018)

Critically, due to the worldwide prevalence of CKD and the associated morbidity and mortality, further clinical and experimental studies, including those using CKD animal models, are needed. Importantly, there should be more clinical trials to evaluate the potential of complementary therapies such as curcumin supplementation on the inflammation process and its associated expression of transcription factors in patients with CKD. To date, there is a dearth of comprehensive investigations that include all prospective inflammatory factors. This systematic review shows there has been a failure to push research to the limit when it comes to investigating inflammatory factors in patients with CKD. This was among the limitations of the present study and may explain the general lack of consensus when investigating anti-inflammatory responses (IL-6, TNF-α, and hs-CRP) to curcumin supplementation. Consequently, among this study's strength, the comprehensive nature and extensive review undertaken of available studies can be mentioned, to name just a few.

In patients with CKD receiving HD, the use of curcumin supplementation was found not to generate a statistically significant impact on the levels of anti-inflammatory biomarkers such as hs-CRP, IL-6, and TNF-α. Therefore, there is an urgent need for comprehensive clinical trials than ever utilizing robust methodologies to finally offer a more accurate appraisal of the effect of curcumin on inflammatory factors in patients with CKD receiving HD. This will help build consensus as to whether curcumin is a beneficial complementary therapy to use within this patient population to enhance their quality of life.

Acknowledgment
The authors express their deepest gratitude to Shahid Beheshti University of Medical Sciences, Shahrekord University of Medical Sciences, and Wright State University Boonshoft School of Medicine.

Conflicts of interest
The authors have declared that there is no conflict of interest.
References

Alvarenga L, Leal VO, Borges NA, Aguiar ASd, Faxén-Irving G, Stenvinkel P, Lindholm B, Mafra D. 2018. Curcumin - A promising nutritional strategy for chronic kidney disease patients. J Funct Foods, 40: 715-721.

Alvarenga L, Salarolli R, Cardozo L, Santos RS, de Brito JS, Kemp JA, Reis D, de Paiva BR, Stenvinkel P, Lindholm B, Fouque D, Mafra D. 2020. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clin Nutr, 39: 3594-3600.

Ammirati AL. 2020. Chronic Kidney Disease. Rev Assoc Med Bras (1992), 66Suppl 1: s03-s09.

Bagherniya M, Soleimani D, Rouhani MH, Askari G, Sathyapalan T, Sahebkar A. 2021. The use of curcumin for the treatment of renal disorders: a systematic review of randomized controlled trials. Adv Exp Med Biol, 1291: 327-343.

Bartaula B, Subedi M, Kumar MM, Shrestha M, Bichha N, Mudbhari B. 2019. Spectrum of complications in chronic kidney disease patients undergoing maintenance hemodialysis: An experience of a tertiary care center in Nepal. Saudi J Kidney Dis Transpl, 30: 208-214.

Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. 2008. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif, 26: 291-299.

Chan WH, Wu HY, Chang WH. 2006. Dosage effects of curcumin on cell death types in a human osteoblast cell line. Food Chem Toxicol, 44: 1362-1371.

GBD Chronic Kidney Disease Collaboration. 2020. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 395: 709-733.

Corsonello A, Freiberger E, Lattanzio F. 2020. The screening for chronic kidney disease among older people across Europe (SCOPE) project: findings from cross-sectional analysis. BMC Geriatr, 20: 316-316.

Crewe C, An YA, Scherer PE. 2017. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest, 127: 74-82.

Ferguson JJA, Abbott KA, Garg ML. 2021. Anti-inflammatory effects of oral supplementation with curcumin: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev, 79: 1043-1066.

Gorabi AM, Razi B, Aslani S, Abbasisard M, Imani D, Sathyapalan T, Sahebkar A. 2021. Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials. Cytokine, 143: 155541.

Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 15: 195-218.

Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A, Narimanyan M, Hovhannisyan A. 2018. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med, 18: 7.

Hasan M, Sutradhar I, Gupta RD, Sarker M. 2018. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol, 19: 291-291.

Jiménez-Osorio AS, García-Niño WR, González-Reyes S, Álvarez-Mejía AE, Guerra-León S, Salazar-Segovia J, Falcón I, de Oca-Solano HM, Madero M, Pedraza-Chaverri J. 2016. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr, 26: 237-244.

Kabodan MH, Kooshki A, Rad M, Tabarraie Y, Sharifipour F. 2018. Investigating the effect of curcumin supplement consumption on systematic inflammation in hemodialysis patients. Int J Life Sci Pharma Res, 8: 39-47.

Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G. 2011. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-
Anti-inflammatory response to curcumin hemodialysis

controlled study. Scand J Urol Nephrol, 45: 365-370.

Kotha RR, Luthria DL. 2019. Curcumin: biological, pharmacological, nutraceutical, and analytical aspects. Molecules, 24: 2930.

Kunnumpakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. 2017. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol, 174: 1325-1348.

Marton LT, Barbalho SM, Sloan KP, Sloan LA, Goulart RA, Araújo AC, Bechara MD. 2022. Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy – a systematic review. Crit Rev Food Sci Nutr, 62: 2140-2157.

Memarzia A, Khazdair MR, Behrouz S, Gholamnezhad Z, Jafarnezhad M, Saadat S, Boskabady MH. 2021. Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. Biofactors, 47: 311-350.

Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C. 2018. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res, 2018: 2180373.

Miller PD. 2014. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep, 3: 542-542.

Mohammad pour A, Dastani M, Salarl R, Radbin S, Mehr S, Ghorbani M, Karimani A, Salarl M. 2019. Curcumin effects on myeloperoxidase, interleukin-18 and matrix metalloproteinase-9 inflammatory biomarkers in patients with unstable angina: A randomized clinical trial. Avicenna J Phytomed, 9: 428-435.

Moreillon JJ, Bowden RG, Deike E, Grggs J, Wilson R, Shelmadine B, Cooke M, Beaujean A. 2013. The use of an anti-inflammatory supplement in patients with chronic kidney disease. J Complement Integr Med, 10: 1-10.

Moreno Velásquez I, Tribaldos Causadias M, Valdés R, Gómez B, Motta J, Cuero C, Herrera-Ballestros V. 2019. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study. BMJ Open, 9: e027229.

Najafi H, Changizi Ashityani S, Sayedzadeh SA, Mohamadi yarjani Z, Fakhri S. 2015. Therapeutic effects of curcumin on the functional disturbances and oxidative stress induced by renal ischemia/reperfusion in rats. Avicenna J Phytomed, 5: 576-586.

Pakfetra M, Akmalı M, Malekmakan L, Dabaghiimanesh M, Khorsand M. 2015. Role of turmeric in oxidative modulation in end-stage renal disease patients. Hemodial Int, 19: 124-131.

Pakfetra M, Basiri F, Malekmakan L, Roozbeh J. 2014. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. J Nephrol, 27: 203-207.

Pretto CR, Winkelmann ER, Hildebrandt LM, Barbosa DA, Colet CF, Stumm EMF. 2020. Quality of life of chronic kidney patients on hemodialysis and related factors. Rev Lat Am Enfermagem, 28: e3327

Rahban M, Habibi-Rezaei M, Mazaheri M, Saso L, Moosavi-Movahedi AA. 2020. Anti-viral potential and modulation of Nrf2 by curcumin: pharmacological implications. Antioxidants, 9: 1228.

Rodrigues HCN, Martins TFP, Santana N, Braga CC, Silva MAC, Cunha LCD, Sugizaki CSA, Freitas A, Costa NA, Peixoto M. 2021. Antioxidant and anti-inflammatory response to curcumin supplementation in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN, 44: 136-142.

Salarollı RT, Alvarezeng L, Carodozo L, Teixeira KTR, de SGML, Lima JD, Rodrigues SD, Nakao LS, Fouque D, Mafra D. 2021. Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study. Int Urol Nephrol, 53: 1231-1238.

Samadian F, Dalili N, Poor-Reza Gholi F, Fattah M, Malih N, Nafar M, Firoozan A, Ahmadpoor P, Samavat S, Ziaie S. 2017. Evaluation of curcumin’s effect on inflammation in hemodialysis patients. Clin Nutr ESPEN, 22: 19-23.

Shafabakhsh R, Asemi Z, Reiner Z, Soleimani A, Aghadavod E, Bahmani F. 2020. The effects of nano-curcumin on metabolic AJP, Vol. 12, No. 6, Nov-Dec 2022 587
status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial. Iran J Kidney Dis, 14: 290-299.

Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, Sestito S, Rapposelli S, Neffe-Skocińska K, Zielińska D, Salehi B, Setzer WN, Dosoky NS, Taheri Y, El Beyrouthy M, Martorell M, Ostrander EA, Suleria HAR, Cho WC, Maroyi A, Martins H, Beyrouthy M, Martorell M, Ostrander EA, Suleria HAR, Cho WC, Maroyi A, Martins H, Parvizian H. 2019. Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy. J Res Med Sci, 24: 77.

Welz AN, Emberger-Klein A, Menrad K. 2018. Why people use herbal medicine: insights from a focus-group study in Germany. BMC Complement Altern Med, 18: 92.

White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV. 2019. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 146: 104280.

Whittaker CF, Miklich MA, Patel RS, Fink JC. 2018. Medication safety principles and practice in CKD. Clin J Am Soc Nephrol, 13: 1738-1746.

Xu G, Gu Y, Yan N, Li Y, Sun L, Li B. 2021. Curcumin functions as an anti-inflammatory and antioxidant agent on arsenic-induced hepatic and kidney injury by inhibiting MAPKs/NF-κB and activating Nrf2 pathways. Environ Toxicol, 36: 2161-2173.

Yang H, Xu W, Zhou Z, Liu J, Li X, Chen L, Weng J, Yu Z. 2015. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes, 123: 360-367.

Yuan H, Ma Q, Ye L, Piao G. 2016. The traditional medicine and modern medicine from natural products. Molecules, 21: 559.